|
|
Blood, 15 June 2007, Vol. 109, No. 12, pp. 5455-5462.
Prepublished online as a Blood First Edition Paper on February 22, 2007; DOI 10.1182/blood-2006-12-063958.
 Previous Article | Next Article 
Submitted December 20, 2006
Accepted February 16, 2007
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
Michael Wang, Liang Zhang, Xiaohong Han, Jing Yang, Jianfei Qian, Sungyoul Hong, Felipe Samaniego, Jorge Romaguera, and Qing Yi*
Dept of Lymphoma & Myeloma, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
* Corresponding author; email: qyi{at}mdanderson.org.
Atiprimod is a novel cationic amphiphilic compound and has been shown to exert antimyeloma effects both in vitro and in mouse experiments. This study was undertaken to evaluate the therapeutic efficacy of atiprimod on mantle cell lymphoma (MCL) and elucidate the mechanism by which it induces cell apoptosis. Atiprimod inhibited the growth and induced apoptosis of MCL cell lines and freshly isolated primary tumor cells in vitro. More importantly, atiprimod significantly inhibited tumor growth in vivo and prolonged the survival of tumor-bearing mice. However, atiprimod also exhibited lower cytotoxicity towards normal lymphocytes. Atiprimod activated c-Jun N-terminal protein kinases (JNK) and upregulated the level of Bax, Bad, and phosphorylated Bcl-2, resulting in release of apoptosis-inducing factor (AIF) and cytochrome c from mitochondria and activation and cleavage of caspase-9, caspase-3, and PARP. However, AIF, but not activation of caspases or PARP, was responsible for apoptosis in MCL cells because an AIF inhibitor, but not pan-caspase or paspase-9 inhibitors, completely abrogated atiprimod-induced apoptosis. Taken together, our results demonstrate that atiprimod displays a strong anti-MCL activity. Cell apoptosis was induced mainly via activation of the AIF pathway. These results support the use of atiprimod as a potential agent in MCL chemotherapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-L. Hsu, L.-Y. Wu, and P.-L. Kuo
Dehydrocostuslactone, a Medicinal Plant-Derived Sesquiterpene Lactone, Induces Apoptosis Coupled to Endoplasmic Reticulum Stress in Liver Cancer Cells
J. Pharmacol. Exp. Ther.,
May 1, 2009;
329(2):
808 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.-L. Kuo, W.-C. Ni, E.-M. Tsai, and Y.-L. Hsu
Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells
Mol. Cancer Ther.,
May 1, 2009;
8(5):
1328 - 1339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Berkova, S. Wang, J. Wise, S. Wang, R. Tao, H. Maeng, D. Hawke, L. W. Kwak, and F. Samaniego
CD74 Is a Regulator of Fas-Mediated Apoptotic Signaling
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
2826 - 2826.
[Abstract]
|
|
|
|
|
|
|
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, P. Lin, Y. Shi, J. Romaguera, L. W. Kwak, et al.
A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma
Clin. Cancer Res.,
April 1, 2008;
14(7):
2154 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
